Landipirdine

Landipirdine
Clinical data
Other names	RO-5025181; RO5025181; SYN-120; SYN120
Drug class	Serotonin 5-HT2A receptor antagonist; Serotonin 5-HT6 receptor antagonist
ATC code	None;
Identifiers
	IUPAC name [(1R)-6-(3-fluorophenyl)sulfonyl-1,2,3,4-tetrahydronaphthalen-1-yl]methylurea;
CAS Number	1000308-25-7;
PubChem CID	46220503;
DrugBank	DB16214;
UNII	J0NX985GDI;
KEGG	D11157;
ChEMBL	ChEMBL1082508;
Chemical and physical data
Formula	C18H19FN2O3S
Molar mass	362.42 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1C[C@H](C2=C(C1)C=C(C=C2)S(=O)(=O)C3=CC=CC(=C3)F)CNC(=O)N;
	InChI InChI=1S/C18H19FN2O3S/c19-14-5-2-6-15(10-14)25(23,24)16-7-8-17-12(9-16)3-1-4-13(17)11-21-18(20)22/h2,5-10,13H,1,3-4,11H2,(H3,20,21,22)/t13-/m0/s1; Key:MTTHRRVVGMPYQG-ZDUSSCGKSA-N;

Landipirdine (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names RO-5025181 and SYN-120) is a serotonin 5-HT_2A and 5-HT₆ receptor antagonist which was under development for the treatment of dementia and cognition disorders but was never marketed.^[1]^[2]^[3] It is taken orally.^[1] The drug was developed by Roche, Accorda Therapeutics, and Biotie Therapies.^[1] It reached phase 2 clinical trials for dementia and phase 1 trials for cognition disorders prior to the discontinuation of its development in 2020.^[1]^[2] Landipirdine was first described in the scientific literature by at least 2010.^[4]^[5]